C3肾小球病和Ig介导的膜增生性肾小球肾炎的实际管理：事实与不确定性
Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties.
作者信息
Fakhouri Fadi, Le Quintrec Moglie, Frémeaux-Bacchi Véronique
机构信息
Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Department of nephrology, Université de Montpellier, CHU de Montpellier, Montpellier, France.
出版信息
Kidney Int. 2020 Nov;98(5):1135-1148. doi: 10.1016/j.kint.2020.05.053. Epub 2020 Jul 3.
In recent years, a substantial body of experimental and clinical work has been devoted to C3 glomerulopathy and Ig-mediated membranoproliferative glomerulonephritis. Despite the rapid accumulation of data, several uncertainties about these 2 rare forms of nephropathies persist. They concern their pathophysiology, classification, clinical course, relevance of biomarkers and of pathology findings, and assessment of the efficacy of the available therapies. The present review discusses the impact of these uncertainties on the clinical management of patients.
近年来，大量的实验和临床工作致力于研究C3肾小球病和免疫球蛋白介导的膜增生性肾小球肾炎。尽管数据迅速积累，但关于这两种罕见肾病形式仍存在一些不确定性。这些不确定性涉及它们的病理生理学、分类、临床病程、生物标志物和病理结果的相关性，以及现有疗法疗效的评估。本综述讨论了这些不确定性对患者临床管理的影响。
Zotero 插件